Business Description
Newron Pharmaceuticals SpA
ISIN : IT0004147952
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.26 | |||||
Equity-to-Asset | -1.16 | |||||
Debt-to-Equity | -1.62 | |||||
Debt-to-EBITDA | -4.04 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.69 | |||||
Beneish M-Score | -3.63 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.6 | |||||
3-Year EBITDA Growth Rate | 15.6 | |||||
3-Year EPS without NRI Growth Rate | 12.4 | |||||
3-Year FCF Growth Rate | 17.3 | |||||
Future 3-5Y Total Revenue Growth Rate | 54.3 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 68.82 | |||||
9-Day RSI | 70.57 | |||||
14-Day RSI | 68.45 | |||||
6-1 Month Momentum % | 54 | |||||
12-1 Month Momentum % | 67.39 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.68 | |||||
Quick Ratio | 0.68 | |||||
Cash Ratio | 0.44 | |||||
Days Sales Outstanding | 80.95 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -0.25 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -127.39 | |||||
Net Margin % | -178.07 | |||||
FCF Margin % | -112.08 | |||||
ROA % | -50.73 | |||||
ROIC % | -53.62 | |||||
ROC (Joel Greenblatt) % | -820.95 | |||||
ROCE % | -79.88 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 15.92 | |||||
PS Ratio | 20.04 | |||||
EV-to-EBIT | -19.59 | |||||
EV-to-Forward-EBIT | 7.17 | |||||
EV-to-EBITDA | -19.92 | |||||
EV-to-Forward-EBITDA | 6.96 | |||||
EV-to-Revenue | 25.84 | |||||
EV-to-Forward-Revenue | 6.28 | |||||
EV-to-FCF | -22.26 | |||||
Price-to-Median-PS-Value | 0.96 | |||||
Earnings Yield (Greenblatt) % | -5.11 | |||||
FCF Yield % | -5.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Newron Pharmaceuticals SpA Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 9.057 | ||
EPS (TTM) (€) | -0.91 | ||
Beta | 1.15 | ||
Volatility % | 79.64 | ||
14-Day RSI | 68.45 | ||
14-Day ATR (€) | 0.592691 | ||
20-Day SMA (€) | 8.722 | ||
12-1 Month Momentum % | 67.39 | ||
52-Week Range (€) | 3.82 - 11.6 | ||
Shares Outstanding (Mil) | 18.63 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Newron Pharmaceuticals SpA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Newron Pharmaceuticals SpA Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Newron Pharmaceuticals SpA Frequently Asked Questions
What is Newron Pharmaceuticals SpA(XTER:NP5)'s stock price today?
When is next earnings date of Newron Pharmaceuticals SpA(XTER:NP5)?
Does Newron Pharmaceuticals SpA(XTER:NP5) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |